A growing list of editing tools can be used to make small changes to the genetic code, tweaking key nucleotides to address the underlying causes of diseases. But bigger edits are often needed, and ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...

A research team led by Rice University's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their ...

The research explores how CRISPR can be used to edit RNA. A team at Montana State University published research that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The ...

Genetic editing holds promise to treat incurable diseases, but the most popular method—CRISPR—sometimes does more harm than good. A new study from University of California San Diego and Yale ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in which genes they transcribe into RNA help determine which type of neuron ...

The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...

Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

In a recent study in Nature Communications, researchers examined the adenosine-to-inosine (A-to-I) nucleoside editing of postmortem and live prefrontal cortical tissues. Researchers found that RNA ...

Boston, Massachusetts-based biotech Ascidian Therapeutics on Wednesday announced a research deal and a licensing agreement worth up to $1.9B with Eli Lilly (LLY) to develop and market kidney disease ...